A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Public ClinicalTrials.gov record NCT06607185. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1a/1b Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Study identification
- NCT ID
- NCT06607185
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Eli Lilly and Company
- Industry
- Enrollment
- 750 participants
Conditions and interventions
Conditions
Interventions
- 5Fluorouracil Drug
- Carboplatin Drug
- Cetuximab Drug
- Cisplatin Drug
- Gemcitabine Drug
- Irinotecan Drug
- LY4066434. Drug
- Leucovorin Drug
- Nab paclitaxel Drug
- Oxaliplatin Drug
- Pembrolizumab Drug
- Pemetrexed Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 20, 2024
- Primary completion
- Dec 31, 2029
- Completion
- Dec 31, 2029
- Last update posted
- Apr 21, 2026
2024 – 2030
United States locations
- U.S. sites
- 26
- U.S. states
- 19
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35233 | — |
| Mayo Clinic | Phoenix | Arizona | 85054 | — |
| City of Hope | Duarte | California | 91010 | — |
| University of California, Los Angeles (UCLA) | Santa Monica | California | 90404 | — |
| University of Colorado Denver | Denver | Colorado | 80220 | — |
| Yale University School of Medicine - Yale Cancer Center | New Haven | Connecticut | 06520-8028 | — |
| The University of Chicago Medical Center (UCMC) | Chicago | Illinois | 60637 | — |
| Indiana University (IU) | Indianapolis | Indiana | 46202 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Henry Ford Health System | Detroit | Michigan | 48202 | — |
| South Texas Accelerated Research Therapeutics (START) Midwest | Grand Rapids | Michigan | 49546 | — |
| Mayo Clinic - Rochester | Rochester | Minnesota | 55905 | — |
| Columbia University | New York | New York | 10032 | — |
| David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Duke University Medical Center | Durham | North Carolina | 27710 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| University of Oklahoma - Health Sciences Center | Oklahoma City | Oklahoma | 73104 | — |
| University of Pittsburgh Medical Center | Pittsburgh | Pennsylvania | 15213 | — |
| Sarah Cannon Research Institute/SCRI | Nashville | Tennessee | 37203 | — |
| SCRI Oncology Partners | Nashville | Tennessee | 37203 | — |
| University of Texas Southwestern | Dallas | Texas | 75244 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| South Texas Accelerated Research Therapeutics (START) | San Antonio | Texas | 78229 | — |
| Virginia Cancer Specialists | Fairfax | Virginia | 22031 | — |
| Swedish Cancer Institute (SCI) | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 30 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06607185, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 21, 2026 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06607185 live on ClinicalTrials.gov.